Adding tarlatamab to maintenance therapy extended survival in small-cell lung cancer
In a phase 3 trial published Oct. 24, 2026, in the New England Journal of Medicine, adding tarlatamab to durvalumab maintenance extended median survival in extensive-stage small-cell lung cancer to 21.1 months…